90403-98-8

Upstream product

• 7076-91-7 (+-)-cis-2-methyl-cyclohexanecarboxylic acid 
• 7077-04-5 2-methyl-1-cyclohexanecarboxylic acid 

Downstream Products

• 5222-62-8 cis-1-acetyl-2-methylcyclohexane 
• 59176-54-4 (+/-)-1-bromo-2c-methyl-cyclohexane-r-carboxylic acid methyl ester 
• 99975-14-1 (+/-)-1-bromo-2c-methyl-cyclohexane-r-carboxylic acid ethyl ester 
• 5222-61-7 (+/-)-1-(trans-2-methyl-cyclohexyl)-ethanone 
• 88960-66-1 3,4-Dichloro-3-methyl-1-(2-methyl-cyclohexyl)-butan-1-one 
• 88960-68-3 C₂₄H₃₆N₂ 
• 88960-69-4 C₂₆H₄₀N₂ 
• 141030-95-7 2-[2-(2-Methyl-cyclohexyl)-pyrrol-1-yl]-ethylamine 
• 141030-98-0 2-[4-Methyl-2-(2-methyl-cyclohexyl)-pyrrol-1-yl]-ethylamine 
• 1029127-89-6 N-(4-(hydroxymethyl)pyridin-2-yl)-2-methylcyclohexanecarboxamide 
• 1403776-26-0 C₁₉H₂₂FN₃O₂ 
• 1201181-69-2 1-(2-methylcyclohexyl)-6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazine 
• 133527-48-7 [4-Methyl-2-(2-methyl-cyclohexyl)-pyrrol-1-yl]-acetic acid 
• 133527-52-3 2-[4-Methyl-2-(2-methyl-cyclohexyl)-pyrrol-1-yl]-propionic acid 

Relevant academic research and scientific papers

Synthesis and evaluation of mefway analogs as ligands for serotonin 5HT1A receptors

18F-Mefway (N-{2-[4-(2′methoxyphenyl)piperazinyl]ethyl}-N-(2-pyridyl)-N-(4′18F-fluoro-methylcyclohexane)carboxamide) was developed and evaluated for use as a PET ligand for imaging 5-HT1A receptors. Ongoing studies of sup

1,2,4 -TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA

This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

SUBSTITUTED TRIAZOLES AND THEIR USE FOR TREATMENT AND/OR PREVENTION NEUROLOGICAL AND PSYCHIATRIC DISORDERS

This invention relates to compounds of formula (I), their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.

Kinetic studies of the epimerization of diastereomeric pyrylium salts

Chiral pyrylium salts are almost unknown in the literature, and none that are epimerizable have been reported prior to our work. Herein, we report two new epimerizable pyryliums and the kinetics of the diastereomeric equilibration of these and one other e

Synthesis of new chiral pyrylium salts and their phosphinine and pyridine derivatives

Despite their versatility, chiral pyryliums are almost unknown in the literature. Reported here is the synthesis of several new chiral pyrylium salts and the corresponding pyridines and phosphinines. This work more than doubles the number of reported chir

Novel Tricyclic Compounds

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Influence of the nature of chiral auxiliaries on the diastereoselective hydrogenation of ortho-substituted benzoic acid derivatives

The diastereoselective hydrogenation of o-toluic acid or o-methoxy benzoic acid covalently bound to different chiral auxiliaries was performed on Rh and Ru supported catalysts. The cis-isomers were formed predominantly, with a diastereoselectivity largely

Asymmetric synthesis of 2-methyl cyclohexane carboxylic acids by heterogeneous catalysis: Mechanistic aspects

The catalytic hydrogenation of (S)-alkyl-N-(2-methylbenzoyl)pyroglutamates was studied over supported rhodium and ruthenium catalysts at room temperature and a pressure of 5 MPa. The reaction was diastereoselective with the predominant formation of (1S,2R)-2-methylcyclohexane carboxylic acid with a diastereomeric excess (de) of up to 96%. The most stable conformation was determined by means of a combination of modelling calculations, NMR spectroscopy and X-ray structural determination. In this conformation, the carbonyl group of the pyroglutamate auxiliary shields one face of the aromatic ring. The observed selectivity may thus be explained by a preferential adsorption at the unshielded face which avoids steric repulsion by the C=O group to result in a cis hydrogenation. The addition of an amine, the nature of the support (alumina or active carbon) or of the metal (Rh or Ru) were shown to give additional stabilisation of the adsorption at the unshielded face to increase the diastereoisomeric excess.